CMC – Page 14 – Pharma.Tips

CPPs not well defined during validation planning – data expectations for filings

Addressing Undefined CPPs During Validation Planning: An Actionable Playbook In the pharmaceutical manufacturing landscape, the identification and definition of Critical Process Parameters (CPPs) during validation planning is pivotal for ensuring…

CPPs not well defined during regulatory submission – ICH Q8/Q11 alignment strategy

Addressing Poorly Defined CPPs During Regulatory Submissions: An ICH Q8/Q11 Alignment Playbook In the fast-paced pharmaceutical landscape, poorly defined Critical Process Parameters (CPPs) during regulatory submissions pose significant risks, particularly…

Process not transferable during regulatory submission – ICH Q8/Q11 alignment strategy

Developing a Strategy for Non-Transferable Processes in Regulatory Submissions The pharmaceutical industry faces significant challenges when processes are deemed non-transferable during regulatory submissions, especially under guidelines set forth by ICH…

Process not transferable during validation planning – regulatory scrutiny risk

Mitigating Risks of Non-Transferable Processes During Validation Planning In the complex landscape of pharmaceutical manufacturing, one critical risk is the inability to transfer processes effectively during validation planning. This oversight…

CPPs not well defined during pilot scale – regulatory scrutiny risk

Mitigating Regulatory Risks: Defining CPPs During Pilot Scale Development In the realm of pharmaceutical manufacturing, the definition of Critical Process Parameters (CPPs) during pilot scale activities often poses significant challenges.…

Process not transferable during pilot scale – ICH Q8/Q11 alignment strategy

Addressing Non-Transferable Processes During Pilot Scale: A Playbook for Alignment with ICH Q8/Q11 In pharmaceutical manufacturing, the transition from laboratory to pilot scale is crucial yet fraught with challenges. When…

CPPs not well defined during pilot scale – preventing downstream validation failure

How to Avoid Validation Failures Due to Poorly Defined CPPs During Pilot Scale Understanding Critical Process Parameters (CPPs) is essential in pharmaceutical manufacturing, particularly during the pilot scale of drug…

Yield loss during optimization during lifecycle optimization – preventing downstream validation failure

Strategies to Mitigate Yield Loss During Lifecycle Optimization to Prevent Validation Failures Yield loss during optimization is a common challenge faced in pharmaceutical manufacturing and process development that can have…

Design space poorly justified during validation planning – process robustness improvement framework

Framework for Improving Process Robustness When Design Space is Poorly Justified In pharmaceutical manufacturing, the justification of the design space during validation planning is crucial to ensuring the robustness of…

Design space poorly justified during pilot scale – process robustness improvement framework

Framework for Addressing Insufficient Justification of Design Space in Pilot Scale Processes During the pharmaceutical manufacturing journey, insufficient justification of the design space during pilot-scale evaluations represents a significant challenge.…

CPPs not well defined during validation planning – ICH Q8/Q11 alignment strategy

Strategies to Address Poorly Defined CPPs During Validation Planning for ICH Q8/Q11 Compliance In pharmaceutical manufacturing, poorly defined Critical Process Parameters (CPPs) during validation planning can lead to significant risks,…

Process variability exceeds limits during regulatory submission – preventing downstream validation failure

Addressing High Process Variability During Regulatory Submission to Avoid Validation Failures In pharmaceutical manufacturing, particularly during regulatory submissions, exceeding process variability limits can lead to significant challenges, including regulatory delays,…